Deal Details

Biohaven Completes $264.5 Million Follow-On Offering

Healthcare

Biohaven follow-on offering

Summary

Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) recently completed an underwritten public offering of 6,451,220 of its common shares, including the full exercise of the underwriters’ option to purchase additional common shares, at a price of $41.00 per share, generating gross proceeds of approximately $264.5 million. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.

Baird served as a Book-Running Manager on this offering.

About

Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. The Company's clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates for cancer. Biohaven Ltd. is headquartered in New Haven, Connecticut.

Healthcare

Biohaven follow-on offering